This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

In its Q4 earnings call to investors on February 25, vaccine developer Vaxcyte expressed optimism about its VAX-31 invasive pneumococcal disease (IPD) vaccine program and discussed the company’s ...

This special issue has come about through a long collaborative process with our contacts at Sartorius Stedim Biotech in Göttingen, Germany. It is the third such sponsored issue that BPI has published ...

Articles In Color Color reprints are printed on 70# enamel paper and can be reproduced in color or in black and white. Color articles reprinted in black and white will be charged black and white ...

Cheryl Scott, Editor in Chief When I was supposed to be writing this editorial, I instead was watching the funeral of former US president James Earl Carter of Georgia. The eulogy and speeches by ...

Cheryl Scott, Editor in Chief. BPI is poised to enter its 23rd year in print. The 21st century has brought many changes to publishing(e.g., from online presence as a “value-add” to an essential) but ...

As of its 2023 guidance on combination and boundary products, the Australian Therapeutic Goods Administration (TGA) has provided context around key regulated product categories: Combination products ...

Pharma giant AstraZeneca announced $3.5 billion in US capital investment that will expand its biopharmaceutical researching and manufacturing footprint in the country by the end of 2026. According to ...

The Cydem VT system combines multiple trusted Beckman Coulter Life Sciences technologies into one advanced platform that empowers lab managers with a far more effective, higher-throughput method for ...

Ensuring regulatory compliance and maintaining high-quality standards is fundamental in the pharmaceutical industry. However, the conventional approach of computer system validation (CSV) is proving ...

Nitrosamines first emerged as a public health concern in 2018 when N-nitrosodimethylamine (NDMA) was discovered in products containing valsartan, an angiotensin II receptor blocker. Subsequently, ...